Last updated on July 2019

Study of Intratumoral CV8102 in cMEL cSCC hnSCC and ACC

Brief description of study

This study evaluates intratumoral administration of CV8102 in patients with advanced melanoma, squamous cell carcinoma of the skin, squamous cell carcinoma of the head and neck, or adenoid cystic carcinoma.

Patients will receive CV8102 as single agent or in combination with SoC anti-PD-1 therapy.

Clinical Study Identifier: NCT03291002

Find a site near you

Start Over

Investigative Site

Erlangen, Germany
  Connect »